FENC: Fennec Pharmaceuticals Inc Average Forecast Price

This chart of Fennec Pharmaceuticals (FENC) stock quotes on the GURU.Markets platform demonstrates the asset's dynamics, with a metric of 17.22. The business is constrained by a small number of pediatric patients and insurance reimbursement issues. However, the unique drug Pedmark protects children's hearing during cancer treatment, ensuring stable profits. This monopoly is maintained by FDA orphan drug status, which precludes the emergence of cheap generics.

FENC (Fennec Pharmaceuticals Inc.) Analyst Consensus Forecast history from 07/04/2022 to 11/11/2026

Analytical breakdowns for Fennec Pharmaceuticals Inc (FENC)

- share price and expert price forecast:

Quote Chart fennecpharma.com|FENC - Analyst Consensus Forecast

- market capitalization information:

Market Value Fennec Pharmaceuticals Inc|FENC - Total Company Value

- shareholders' equity book value data:

Equity per Share Fennec Pharmaceuticals|FENC - Book Capitalization|Market Cap to Net Assets Ratio fennecpharma.com|FENC - Company Total Assets

- issuer credit burden and liquidity indicators:

- net income and valuation multiples indicators:

FENC - Net Profit|Projected Future Earnings Fennec Pharmaceuticals|FENC - Price to Earnings Ratio|Future Price to Earnings Fennec Pharma|FENC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Fennec Pharmaceuticals Inc|FENC - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Fennec Pharmaceuticals|FENC - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months fennecpharma.com|FENC - Earnings growth in current year|Expected earnings per share growth for next year Fennec Pharmaceuticals

Fundamental company analysis:fennecpharma.com (FENC)

Manufactured product of Fennec Pharmaceuticals Inc.

An analysis of the consensus valuation for Fennec Pharmaceuticals (FENC) confirms the issuer's status as a stable player in the oncology support sector. This metric aggregates average expert expectations for the fair value, where the trend line shifting into a horizontal plateau signals the achievement of market equilibrium, supported by the seamless operation of contracted production lines and rigorous equipment quality control.

Competing companies